Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Innovation Council · Running

TwistedNano Twisted nanophotonic technology for integrated chiroptical sensing of drugs on a chip

Coordinator
Universita Degli Studi Dell'aquila, Italy
Runs
1 April 2022 to 31 July 2026
Status
Running
EU funding
€3.7m
Total cost
€3.7m
Partners
10 organisations in 6 countries
Type
European Innovation Council
Grant agreement
101046424

What the project is doing

In the project's own words, from its summary on CORDIS.

The quest for new medical drugs demands reliable, ultrasensitive and fast techniques to identify, refine and test small volumes of candidates for clinical trials. The efficacy of pharmaceuticals depends to a large extent on their chiral composition, and thus enantiomeric purity and selectivity is an important issue for the development of new drugs and to test their biotoxicity. TwistedNano addresses this need with a new generation of integrated nanophotonic devices enabling ultrasensitive chiroptical spectroscopy of sub-nanolitre volumes, revolutionizing at-source the sensing technological toolbox for drug discovery and nanomedicine.

Because of governmental regulations, agencies require pharmaceutical manufacturers to investigate systematically most of drug enantiomers to determine their safety/efficacy. Thus, the development of fast, compact and accurate chiral sensing on a chip is one of the current primary targets of the nanomedicine industry, constituting a growing market that is already exceeding 100 billion Euros. TwistedNano will result in a photonics-enabled chiral sensing technology that integrates vectorial structured light fields with almost arbitrary control onto a microfluidic chip, providing groundbreaking advantages compared to current instrumentation: (i) remote/distributed analysis, (ii) reduced sample consumption, (iii) cost reduction, (iv) parallelization, (v) increased diagnostic speed and sensitivity.

Key elements developed for optofluidic integration include photonic crystal fibers, photonic nanostructures, and metasurfaces operating in close synergy with cutting-edge chiroptical spectroscopic techniques. In the mid-term, TwistedNano will not only lay the foundations of a new lab-on-chip chiral sensing technology revolutionizing drug discovery, theranostics and nanomedicine, but also open a plethora of disruptive applications such as characterization of minute amounts of viruses and macromolecules in general.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Dell'aquilaL AquilaItalyCoordinator
Ecole Polytechnique Federale De LausanneLausanneSwitzerlandAssociatedpartner
University of CyprusNicosiaCyprusParticipant
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften eVMunchenGermanyParticipant
Fundacio Institut De Ciencies FotoniquesCastelldefelsSpainParticipant
Centre National De La Recherche Scientifique CNRSParisFranceParticipant
Universite Cote D'azurNiceFranceThird party
Dompe Farmaceutici SpAMilanoItalyParticipant
Fondazione Istituto Italiano Di TecnologiaGenovaItalyParticipant
Foresee Biosystems SRLGenovaItalyParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI